Phaseline

Companies › Therini Bio

Therini Bio: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Ophthalmology, Neurology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
THN391
Intravitreal injection (mechanism not specified)
–Phase 1Diabetic Macular EdemaMar 2027
THN391–Phase 1Alzheimer Disease, Early OnsetMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06701721THN391Phase 1Diabetic Macular EdemaOphthalmologyMar 2027
NCT06814730THN391Phase 1Alzheimer Disease, Early OnsetNeurologyMar 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.